Children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia now have a new reason to pay attention.

Outpatient monitoring of CAR T-cell therapy reduces healthcare resource utilization and hospital days without impacting 30-day mortality, finds ASCO study.

Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived ...

New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants.    | Orca Bio has jumped into ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

A UF Health oncologist answers the most common questions about cell therapy, from who qualifies to how it differs from ...

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

By Yiqing Wang/WHRO State lawmakers have budgeted nearly $15 million over two years to help Virginia Medicaid cover gene ...